Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • Arabic
      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS

Dendritic Cell Cancer Vaccine Market Size Will Reach USD 1,841.54 Million By 2032, at 11.9% CAGR Growth: Polaris Market Research

Polaris Market Research Logo

News provided by

Polaris Market Research

Jan 12, 2023, 09:30 ET

Share this article

Share toX

Share this article

Share toX

NEW YORK, Jan. 12, 2023 /PRNewswire/ -- A latest research report [115+] pages with 360-Degree visibility, titled "Dendritic Cell Cancer Vaccine Market Share, Size, Trends, Industry Analysis Report, By Product; By End-Use; By Region; Segment Forecast, 2023-2032" published by Polaris Market Research in its research repository.

As per recent research study, the global dendritic cell cancer vaccine market size was valued at USD 596.65 million in 2022 and is expected to reach USD 1,841.54 Million by 2032, growing at a CAGR of 11.9% during the forecast period.

What is Dendritic Cell Cancer Vaccines? How Big is Dendritic Cell Cancer Vaccine Market Size?

  • Overview

Dendritic cell cancer vaccines induce specific immune responses that can individually eliminate target cells. Many studies are being conducted to explore DC vaccination to cure hematological malignancies, including acute myeloid leukemia and myelodysplastic syndromes, as well as other non-leukemia malignancies. The rapidly rising demand for the dendritic cell cancer vaccine market can be attributed to the fact that due to their capacity for antigen presentation, DCs are principal organizers in the induction of antitumor immunity.

The growth of the market is credited to elements such as escalating clinical trial activity connected to cancer vaccines, increasing demand for mRNA-based vaccines together with expanding cancer remedies. The increasing demand for constructive and customized treatments is influencing the market's growth.

Request Sample Copy of Dendritic Cell Cancer Vaccine Market Research Report @ https://www.polarismarketresearch.com/industry-analysis/dendritic-cell-cancer-vaccine-market/request-for-sample

(The sample of this report is readily available on request. The report sample contains a brief introduction to the research report, Table of Contents, Graphical introduction of regional analysis, Top players in the market with their revenue analysis and our research methodology.)

Our Sample Report May Includes:

  • 2030 Updated Report Introduction, Overview, and In-depth industry analysis
  • 115+ Pages Research Report (Inclusion of Updated Research)
  • Provide Chapter-wise guidance on Request
  • 2022 Updated Regional Analysis with Graphical Representation of Size, Share & Trends
  • Includes Updated List of table & figures
  • Updated Report Includes Top Market Players with their Business Strategy, Sales Volume, and Revenue Analysis

Some of the Top Market Players Are:

  • 3M Company
  • Activartis
  • Argos Therapeutics
  • Batavia Bioservices
  • DanDrit Biotech Corporation
  • DCPrime
  • Elios Therapeutics
  • GlaxoSmithKline
  • ImmunoCellular Therapeutics
  • Sanpower Corporation

To know an additional revised list of top market players, request a sample report, 2023 - 2032: https://www.polarismarketresearch.com/industry-analysis/dendritic-cell-cancer-vaccine-market/request-for-sample

Key Highlights of the Report

  • Qualitative and quantitative analysis of the market based on segmentation, including both economic as well as non-economic factors
  • Supplying market value data for each segment and sub-segment
  • Points to the region and segment that is anticipated to witness the fastest growth
  • Analysis by geography underscoring the intake of the product or service in the region as well as designating the factors that are impacting the market within each region
  • Substantial company profiles consisting of company overview, company insights, product benchmarking, and SWOT analyses for major market players

Growth Driving Factors

  • An increasing number of cancer patients globally pushes the market

The market is gaining traction due to the escalating number of cancer patients globally. The alterations in lifestyle, such as chewing tobacco, smoking, and drinking alcohol, have notably enhanced the figure of cancer patients globally, thereby offering an ascend to the market. The dendritic cell cancer vaccine market size is expanding as it is attracting the attention of several prospective investors and stakeholders due to a remunerative advancement in the pipeline.

The dendritic cell vaccine immunotherapy has transformed the market with its exciting new range of techniques. The dendritic cell cancer vaccine market sales are soaring as, in contrast with chemotherapy and radiation therapy, these new techniques are bereft of side effects. The global healthcare industry for cancer was in pressing need of encouraging treatment where patients could have increased five-year survival rate, slightest side effects, improvised targeting capacity of the controlled cells, and many more.

Directly Purchase a copy of report with TOC @ https://www.polarismarketresearch.com/checkouts/19491

Recent developments

·  In June 2018, Northwest Bio-therapeutics secured FDA clearance for its dendritic cell-based vaccine, DCVax-L, utilized to cure glioblastoma cancers. Its clinical globe exemplified that many patients lived for more than a year after getting the immunization.

Segmental Analysis

  • The sipuleucel-T segment emerged with the highest revenue share

Based on product, the Sipuleucel-T segment emerged with the highest revenue share. Sipuleucel-T's potential to profitably boost an individual's immunity against tumor cells escalates its market demand. The vaccine was licensed by the US Food and Drug Administration in 2010 for the cure of castrate-resistant prostate cancer. Dendritic cell cancer vaccine market demand is rising as Sipuleucel-T increases immunity with sparse adverse effects and enhances the survivor's longevity.

  • Adults segment dominated the market

Based on end use, the adults segment dominated the market due to escalated cases of malignancies globally. Dendritic cell cancer vaccine market trends include several researchers globally attempting to carry out substantial studies to generate feasible vaccine candidates so that possible treatment techniques can be accomplished.

Inquire more about this report before purchase @ https://www.polarismarketresearch.com/industry-analysis/dendritic-cell-cancer-vaccine-market/inquire-before-buying

(Inquire a report quote OR available discount offers to the sales team before purchase.)

Dendritic Cell Cancer Vaccine Market: Report Scope

Report Attribute

Details

Revenue forecast in 2032

USD 1,841.54 Million

Market size value in 2023

USD 667.29 Million

Expected CAGR Growth

11.9 % from 2023 - 2032

Base Year

2021

Forecast Year

2023 - 2032

Top Market Players

3M Company, Activartis, Argos Therapeutics, Batavia Bioservices, , DanDrit Biotech Corporation, DCPrime, Elios Therapeutics, GlaxoSmithKline, ImmunoCellular Therapeutics, Sanpower Corporation

Segments Covered

By Product, By End-Use, By Region

Customization Options

Customized purchase options are available to meet any research needs. Explore customized purchase options

Geographic Overview

  • Substantially funded research studies to drive the North American market

North America held the largest dendritic cell cancer vaccine market share due to an unusual increase in cancer cases and considerable research studies funded by university research institutes and pharmaceutical behemoths. For instance, researchers at Memorial Sloan Kettering Cancer Centre in the United States have been studying mRNA vaccine technology. They will debate the phase 1 trial outcomes at the American Society of Clinical Oncology's annual conference. It is a known fact that mRNA vaccines boost dendritic cells to generate neo-antigen proteins against cancerous cells.

Europe is anticipated to possess sizeable market expansion in the future years. This can be attributed to the growing demand for cancer vaccines, growing cancer cases, and heightened reinforcement for research projects from the cancer societies, all of which commit to the market's growth.

Browse the Detail Report "Dendritic Cell Cancer Vaccine Market Share, Size, Trends, Industry Analysis Report, By Product; By End-Use; By Region; Segment Forecast, 2023-2032" with in-depth TOC: https://www.polarismarketresearch.com/industry-analysis/dendritic-cell-cancer-vaccine-market  

For Additional Information OR Media Enquiry, Please Mail At: [email protected]

Polaris Market Research has segmented the dendritic cell cancer vaccine market report based on product, end-use, and region:

By Product Outlook

  • CreaVax
  • Sipuleucel-T
  • Others

By End Use Outlook

  • Paediatrics
  • Adults

By Region Outlook

  • North America (U.S., Canada)
  • Europe (France, Germany, UK, Italy, Netherlands, Spain, Russia)
  • Asia Pacific (Japan, China, India, Malaysia, Indonesia. South Korea)
  • Latin America (Brazil, Mexico, Argentina)
  • Middle East & Africa (Saudi Arabia, UAE, Israel, South Africa)

About Polaris Market Research

Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for PMR's clientele spread across different enterprises. We at Polaris are obliged to serve PMR's diverse customer base present across the industries of healthcare, technology, semi-conductors and chemicals among various other industries present around the world. We strive to provide PMR's customers with updated information on innovative technologies, high growth markets, emerging business environments and latest business-centric applications, thereby helping them always to make informed decisions and leverage new opportunities. Adept with a highly competent, experienced and extremely qualified team of experts comprising SMEs, analysts and consultants, we at Polaris endeavor to deliver value-added business solutions to PMR's customers.

Contact: 
Likhil G 
30 Wall Street 
8th Floor, 
New York City, NY 10005, 
United States 
Phone: +1-929 297-9727 
Email: [email protected] 
Web: https://www.polarismarketresearch.com 
Follow US: LinkedIn | twitter

Logo: https://mma.prnewswire.com/media/1316207/Polaris_Market_Research_Logo.jpg

SOURCE Polaris Market Research

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

icon3
440k+
Newsrooms &
Influencers
icon1
9k+
Digital Media
Outlets
icon2
270k+
Journalists
Opted In
GET STARTED

Modal title

Contact PR Newswire

  • Call PR Newswire at 888-776-0942
    from 8 AM - 9 PM ET
  • Chat with an Expert
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Italy
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • Vietnam

My Services

  • All New Releases
  • Platform Login
  • ProfNet
  • Data Privacy

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Platform Login
  • ProfNet
Call PR Newswire at
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookies
Copyright © 2025 Cision US Inc.